GCP CAPA SUPPORT SERVICES
BioBoston CRO provides Good Clinical Practice Corrective and Preventive Action support for sponsors, sites, and clinical vendors that need to investigate significant deviations, audit or inspection findings, recurring quality signals, or control failures and develop evidence-based remediation. Support can include problem definition, containment, root-cause analysis, CAPA planning, implementation oversight, evidence review, and effectiveness checks.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
Clarify the problem, affected scope, risk, root cause, corrective and preventive actions, implementation evidence, and effectiveness criteria.
Determine whether recurrence reflects training, procedure, system, responsibility, workload, communication, oversight, data, or governance failures.
Independently assess investigation logic, action-to-cause alignment, ownership, evidence, due dates, residual risk, and effectiveness.
when needed
Problems
The service is most valuable when the team can identify the specific control gap, decision, deliverable, or
recovery need rather than requesting generic capacity.
Scope
The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures,
the review model, and the target milestone.
Deliverables
Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.
Client inputs
The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.
Process
1. Confirm the purpose, current state, intended use, milestone, stakeholders, responsibilities, systems or vendors, and agreed deliverables.
2. Review available source materials, prior decisions, procedures, evidence, and open issues; issue a focused gap and dependency list.
3. Develop the work plan, specifications, document, assessment, or control package included in scope.
4. Coordinate review through named sponsor and cross-functional decision owners and maintain a controlled open-item and comment process.
5. Perform the agreed technical, quality, consistency, or operational checks and document remaining risks or limitations.
6. Prepare the approved handoff, implementation, submission, remediation, archive, or next-step package as defined in scope.
Considerations
The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.
Engagement options
BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.
BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.
BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.
RELATED SERVICES
Identify, document, and risk-rank independent audit findings that may require corrective and preventive action.
Test whether remediation is implemented, evidenced, understood, and retrievable before an inspection.
Integrate CAPA trends and systemic risks into the broader clinical quality-management framework.
Strengthen sponsor control when the CAPA involves delegated vendor activities or oversight evidence.
Expertise
GCP CAPA experience should match the type and significance of the event, study or system context,
participant and data risk, applicable requirements, vendor interfaces, and inspection implications.
RESOURCES
Explore the following resources for additional insights and information relevant to this service.
A planned checklist for problem definition, containment, evidence, extent, chronology, causal analysis, actions, and effectiveness.
A planned guide to direct causes, contributing factors, systemic causes, detection failures, and oversight weaknesses.
A planned template for criteria, measures, period, population, sampling, owner, evidence, results, and closure decision.
FAQs
Support may include containment review, problem definition, evidence collection, affected-scope analysis, root-cause analysis, action planning, response drafting, implementation evidence, closure review, and effectiveness checks.
Yes. The investigation should connect the finding to applicable requirements, event evidence, affected scope, risk, causal analysis, actions, owners, implementation evidence, and effectiveness.
Sometimes training is appropriate, but it should not be the default. The investigation must determine whether process, system, design, workload, interfaces, supervision, governance, or detection controls also contributed.
Yes. An independent review can assess problem definition, evidence, scope, risk, cause, action-to-cause alignment, deadlines, implementation evidence, effectiveness, and sponsor oversight.
The effectiveness check should use predefined criteria, measures, time period, population or sample, evidence sources, owner, and decision rules that test whether the control improved and recurrence risk is acceptably managed.
No. A well-supported CAPA can improve the quality and defensibility of the response, but authorities determine whether the investigation and remediation are adequate.
PROJECT FORM
Share the finding or quality event, affected study or system, immediate actions, current investigation, due date, prior recurrence, and the support you need. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion identifies the event, requirement, risk, affected scope, evidence, current investigation, prior recurrence, owners, and deadline. BioBoston can then define the investigation, CAPA, response, implementation, or effectiveness-review scope.
